-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy

Reuters·05/13/2026 11:01:47

Please log in to view news